NCT01957644 - Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 6, 2013

Primary Completion Date

December 16, 2016

Study Completion Date

December 16, 2016

Conditions

Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic

Interventions

DRUG

Azacitidine

DRUG

Volasertib

Trial Locations (14)

1230.33.33002 Boehringer Ingelheim Investigational Site, Marseille

1230.33.33001 Boehringer Ingelheim Investigational Site, Paris

1230.33.49011 Boehringer Ingelheim Investigational Site, Berlin

1230.33.49002 Boehringer Ingelheim Investigational Site, Dresden

1230.33.49001 Boehringer Ingelheim Investigational Site, Düsseldorf

1230.33.49005 Boehringer Ingelheim Investigational Site, Frankfurt am Main

1230.33.49004 Boehringer Ingelheim Investigational Site, Freiburg im Breisgau

1230.33.49010 Boehringer Ingelheim Investigational Site, Hamburg

1230.33.49008 Boehringer Ingelheim Investigational Site, Hanover

1230.33.49012 Boehringer Ingelheim Investigational Site, Kassel

1230.33.49014 Boehringer Ingelheim Investigational Site, Leipzig

1230.33.49009 Boehringer Ingelheim Investigational Site, Mannheim

1230.33.49006 Boehringer Ingelheim Investigational Site, München

1230.33.49003 Boehringer Ingelheim Investigational Site, Ulm